雷珠单抗治疗糖尿病黄斑水肿患者的长期结局:一项4年研究
该研究在常规临床环境中随访80例糖尿病黄斑水肿患者的102只眼共4年,所有眼先接受3次每月0.5 mg雷珠单抗负荷注射,第3至48个月按需再注射。4年时最佳矫正视力平均提高6.6个ETDRS字母(P < 0.001),4年平均注射7.7 ± 3.4次;作者结论为负荷剂量后的视力获益在按需方案下得以维持。
要点
- 4年时最佳矫正视力平均提高6.6个ETDRS字母(P < 0.001)。
- 4年平均注射雷珠单抗7.7 ± 3.4次,第1至4年分别为4.7、1.4、0.7、0.9次。
- 既往接受局灶/格栅激光者与未治疗者在所需注射次数上无差异。
核心结论
- 初始负荷剂量后获得的最佳矫正视力提升在按需方案下随时间得以维持,研究期间维持最佳矫正视力所需注射次数较低。
研究设计与样本
- 在常规临床环境中随访80例患者的102只眼共4年,所有眼接受3次每月0.5 mg雷珠单抗负荷注射,第3至48个月根据疾病活动度按需再注射。
主要发现
- 排除死亡者后,82%的研究眼完成了4年随访。
- 4年时最佳矫正视力平均提高6.6个ETDRS字母(P < 0.001)。
- 4年平均接受雷珠单抗注射7.7 ± 3.4次。
- 第1至4年平均注射次数分别为4.7(1.1)、1.4(1.4)、0.7(1.1)、0.9(1.4)次。
- 既往接受局灶/格栅激光者与未治疗者在所需注射次数上无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the long-time visual outcome in patients with diabetic macular edema treated with ranibizumab in an ordinary clinical setting. METHODS: One hundred two eyes of 80 patients were followed for 4 years. All patients received a loading dose of 3 monthly ranibizumab 0.5-mg injections. From Month 3 to Month 48, patients received ranibizumab reinjections pro re nata based on disease activity. RESULTS: Excluding deaths, the 4-year visit was completed by 82% of the study eyes. The best-corrected visual acuity improved by 6.6 Early Treatment Diabetic Retinopathy Study letters at 4 years (P < 0.001). The patients received a mean of 7.7 ± 3.4 ranibizumab injections for 4 years. The number of injections (mean ± SD) given were 4.7 (1.1), 1.4 (1.4), 0.7 (1.1), and 0.9 (1.4) during Years 1 to 4, respectively. No difference in the injections needed was seen between patients who had previously received focal/grid laser and treatment-naive subjects. CONCLUSION: The gain in the best-corrected visual acuity achieved after the initial loading dose was sustained over time with a pro re nata regimen. The number of injections needed to maintain the best-corrected visual acuity was low during the study period.
引用
- Epstein D, Amrén U. LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: A 4-Year Study. Retina. 2018. PMID: 28323678. doi:10.1097/IAE.0000000000001501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。